Butyrylcholinesterase and 24 h-urinary copper excretion as compliance assessment in long-term treated Wilson’s disease

Butyrylcholinesterase and 24 h-urinary copper excretion as compliance assessment in long-term treated Wilson’s disease

Background and aim of the studyCompliance is the most challenging aspect of long-term therapy in Wilson’s disease (WD). Evidence is presented that butyrylcholinesterase (CHE) can be used as a sensitive biomarker to detect compliance problems in long-term treated WD-patients.MethodsFor the present re...

Full description

Saved in:
Bibliographic Details
Main Authors: Harald Hefter, Max Novak, Dietmar Rosenthal, Sven G. Meuth, Tom Luedde, Philipp Albrecht, Christian J. Hartmann, Sara Samadzadeh
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Neurology
Subjects:
Wilson’s disease
butyrylcholinesterase
24 h-urinary copper excretion
compliance
long-term treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2025.1553573/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2025.1553573/full

Similar Items